Physician profile
Daniel P Mirda
NPI 1811963317
$50,146.14
in general payments reported to CMS, 2019-2025
57 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,954 · 2021: $5,627 · 2022: $2,351 · 2023: $23K · 2024: $2,476 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $3,985 · Consulting Fee: $3,426 · Travel and Lodging: $2,095 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,882.27 |
| Food and Beverage | $3,985.00 |
| Consulting Fee | $3,425.50 |
| Travel and Lodging | $2,095.44 |
| Education | $161.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18,187.38 | 2021-2023 | |
| Eli Lilly and Company | $7,987.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $5,380.09 | 2019-2024 | Opdivo, Camzyos |
| Pfizer INC. | $3,390.48 | 2019-2025 | |
| Seagen INC. | $3,186.23 | 2019-2023 | |
| Celgene Corporation | $2,180.68 | 2020-2025 | Opdivo, Reblozyl, Opdualag |
| Eisai INC. | $1,865.01 | 2023 | |
| Gilead Sciences, INC. | $1,337.12 | 2021-2025 | Trodelvy |
| Immunomedics, INC. | $1,300.00 | 2020 | |
| Janssen Biotech, INC. | $659.59 | 2020-2025 | Rybrevant, Erleada, Akeega |
| Lilly USA, LLC | $612.77 | 2019-2025 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $584.78 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Amgen INC. | $314.31 | 2021-2023 | Lumakras |
| Genentech USA, INC. | $309.66 | 2019-2025 | Tecentriq, Phesgo, Itovebi |
| Abbvie INC. | $251.67 | 2019-2024 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mirda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.